Intravenous administration of cyclosporine (Sandimmune to rapidly and effectively achieve therapeutic serum levels in transplant recipients has been the treatment standard in many transplantation centers.
With the development of microemulsion cyclosporine (Neoral), that standard is changing.
Neoral has greater bioavailability than the oral form of Sandimmune and, consequently can be more efficacious and cost-effective.
To test this hypothesis, we undertook a retrospective study of Sandimmune and Neoral in the treatment of 66 children who underwent uncomplicated orthotopic liver transplantation in the Texas Medical Center between April 1991 and December 1997.
Both forms of cyclosporine were evaluated iii terms of in-patient treatment cost, recuperative time in the intensive care unit and duration of hospitalization.
Twenty-two patients were treated orally with Neoral, and 44 patients were treated intravenously with Sandimmune for a mean time of 14 d. Once the blood concentration of Sandimmune reached a steady state. as confirmed by daily measurements of the trough level, the patients in the Sandimmune group were converted to oral cyclosporine.
None of the 22 patients treated with Neoral required intravenous treatment.
The mean time spent in the intensive care unit was 4 d for the Neoral group and 5.5 d for the Sandimmune group. (...)
Mots-clés Pascal : Homotransplantation, Foie, Enfant, Homme, Ciclosporine, Forme pharmaceutique, Durée, Hospitalisation, Traitement, Chimiothérapie, Coût, Economie santé, Efficacité traitement, Etude comparative, Transplantation, Chirurgie, Immunodépresseur
Mots-clés Pascal anglais : Homotransplantation, Liver, Child, Human, Ciclosporin, Dosage form, Duration, Hospitalization, Treatment, Chemotherapy, Costs, Health economy, Treatment efficiency, Comparative study, Transplantation, Surgery, Immunosuppressive agent
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0027179
Code Inist : 002B25G03. Création : 31/05/1999.